FOXM1 and prostate carcinoma: In cancer, FOXM1 is generally considered a marker for poor prognosis in cancer survival studies [22], often as a co-effector with other cancer master regulators [23], such as CENPF in prostate cancer [24] and MYB in lymphoma [25].